Please provide your email address to receive an email when new articles are posted on . Approximately 70% of previous nonresponders to the HBV vaccine developed a response after HCV treatment and cure ...

HBcAb-positive, HBsAg-negative people with HIV can safely switch from tenofovir-containing ART without clinically significant ...

This “Spark and Fan” treatment strategy could potentially offer a simple and well tolerated solution for a wide range of future HBV functional cure regimens for patients worldwide.” — Dr. Sue Currie, ...

China has approved the world's first domestically developed drug designed to achieve a functional cure for hepatitis B, ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

SEATTLE — The effort to find a cure for hepatitis B faces steep challenges, Anna Suk-Fong Lok, MD, told Healio after her plenary presentation at the Conference for Retroviruses and Opportunistic ...

China has approved the world's first domestically developed drug designed to achieve a functional cure for hepatitis B, ...

Particularities of the HBV cycle that favour the development of chronic infection (centre), the clinical challenges stemming from these biological characteristics (top) and the opportunities currently ...

– Oral presentation highlights significant reduction in HBV DNA integration and other clinically-relevant biomarkers from the EBT-107 therapeutic candidate in preclinical mouse models WATERTOWN, Mass.

Arbutus aims to begin combination therapies between their flagship TKM-HBV and other HBV inhibitors they are generating by 2017. It is critical that the Phase II TKM-HBV trials go smoothly if Arbutus ...